{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Amino+Acid&page=35",
    "query": {
      "intervention": "Amino Acid",
      "page": 35
    },
    "page_size": 10
  },
  "pagination": {
    "page": 35,
    "page_size": 10,
    "total_count": 16003,
    "total_pages": 1601,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Amino+Acid&page=36&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Amino+Acid&page=34&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T07:58:26.670Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00254436",
      "title": "A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastrointestinal Cancer",
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Procrit (epoetin alfa)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2001-10-31",
      "completion_date": "2004-06-29",
      "has_results": false,
      "last_update_posted_date": "2018-10-25",
      "last_synced_at": "2026-11-19T07:58:26.670Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00254436"
    },
    {
      "nct_id": "NCT00010309",
      "title": "Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "MART-1 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp100 antigen",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-01-06",
      "last_synced_at": "2026-11-19T07:58:26.670Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Cambridge, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00010309"
    },
    {
      "nct_id": "NCT00334932",
      "title": "Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "pegylated liposomal doxorubicin hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Herbert Irving Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2006-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-01-10",
      "last_synced_at": "2026-11-19T07:58:26.670Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • New York, New York",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00334932"
    },
    {
      "nct_id": "NCT07643493",
      "title": "CleaRRAflow: Isotonic Solution vs. TPA for IVH Clearance",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Tissue Plasminogen Activator",
        "Intraventricular Brain Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Tissue Plasminogen Activator (tPA)",
          "type": "DRUG"
        },
        {
          "name": "Isotonic solution",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "David Dornbos",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 80,
      "start_date": "2026-07-31",
      "completion_date": "2029-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-11-19T07:58:26.670Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07643493"
    },
    {
      "nct_id": "NCT01279616",
      "title": "A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Fludarabine monophosphate",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "ATG",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 8,
      "start_date": "2010-09",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2019-04-03",
      "last_synced_at": "2026-11-19T07:58:26.670Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01279616"
    },
    {
      "nct_id": "NCT01119677",
      "title": "A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Avonex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 120,
      "start_date": "2010-05-05",
      "completion_date": "2010-10-23",
      "has_results": false,
      "last_update_posted_date": "2017-11-17",
      "last_synced_at": "2026-11-19T07:58:26.670Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01119677"
    },
    {
      "nct_id": "NCT00524277",
      "title": "Vaccine Therapy in Treating Patients With Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "GP2 peptide + GM-CSF vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GM-CSF (sargramostim)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AE37 + GM-CSF vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "San Antonio Military Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 456,
      "start_date": "2007-01",
      "completion_date": "2017-03-31",
      "has_results": false,
      "last_update_posted_date": "2020-03-30",
      "last_synced_at": "2026-11-19T07:58:26.670Z",
      "location_count": 11,
      "location_summary": "Washington D.C., District of Columbia • Honolulu, Hawaii • Baltimore, Maryland + 7 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00524277"
    },
    {
      "nct_id": "NCT04681677",
      "title": "Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Recurrent Glioblastoma",
        "GBM",
        "Recurrent GBM"
      ],
      "interventions": [
        {
          "name": "Radiation: Intra-operative Radiation Therapy - IORT",
          "type": "RADIATION"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Xoft, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2021-11-02",
      "completion_date": "2024-04-24",
      "has_results": false,
      "last_update_posted_date": "2024-04-26",
      "last_synced_at": "2026-11-19T07:58:26.670Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04681677"
    },
    {
      "nct_id": "NCT00371033",
      "title": "Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)"
      ],
      "interventions": [
        {
          "name": "Pregabalin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 324,
      "start_date": "2006-03",
      "completion_date": "2008-04-30",
      "has_results": true,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-11-19T07:58:26.670Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Stanford, California • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00371033"
    },
    {
      "nct_id": "NCT06050668",
      "title": "Essential Amino Acid Supplementation for Femoral Fragility Fractures",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Femoral Fracture",
        "Fragility Fracture",
        "Muscle Atrophy"
      ],
      "interventions": [
        {
          "name": "Essential Amino Acid Supplementation",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Michael C Willey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2024-06-17",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-11-19T07:58:26.670Z",
      "location_count": 2,
      "location_summary": "Iowa City, Iowa • Eugene, Oregon",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06050668"
    }
  ]
}